Argenta is pleased to announce the appointment of Simon Bellamy as its new Business Development Director, starting today. In this role, Simon will help drive the company’s strategic growth initiatives for its Contract Development and Manufacturing Organisation (CDMO) in Europe and APAC, and play a critical role in driving Argenta’s expansion plans.
Simon will report to and work closely with Mark Bridgewater, Chief Business and Growth Officer. As Business Development Director, he will identify, evaluate, and execute on new business opportunities as well as establish and maintain key relationships with customers, partners, and stakeholders.
"We are excited to have Simon join our team," said Mark Bridgewater. "With his extensive experience and the ability to understand and anticipate client needs, we are confident that he will be instrumental in helping us achieve our growth objectives and take Argenta to the next level."
Simon brings over 30 years of experience in the pharmaceutical and CDMO industry. In previous roles, he has consistently delivered exceptional results through effective business development strategies and relationship building. Prior to joining Argenta, Simon was Director, Strategic Partnership – Europe at Curia (formerly known as AMRI). Before that, he was Account Director for several divisions at Catalent Pharma Solutions.
Simon said, “I am excited to be joining Argenta and looking forward to driving new business growth as well as supporting our existing clients.”
Founded in New Zealand, Argenta’s talented and committed employees are dedicated to delivering excellence in animal health to customers around the world. With research and/or GMP manufacturing operations in Germany, New Zealand, Spain, the United Kingdom, and the United States, Argenta holds a unique position as the only combined global contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) specialising in animal health and nutrition.
We operate from Molecule to Market in partnership with customers of all sizes from all corners of the world, supporting their research and development, clinical research, regulatory, scale-up and manufacturing needs along the veterinary product development journey.
The day-to-day ethos that drives us forward is a mission focused on global partnerships, a Molecule to Market approach, and innovation. At the core of our business and organisation is collaboration – among our global employee base and with our customers.
Please don’t hesitate to get in touch if you are interested in our services.